Infliximab does not increase the risk of early postoperative complications in UC patients after a three-stage restorative proctocolectomy with IPAA
Abstract
Introduction and aim: Patients with ulcerative colitis (UC) treated with infliximab (IFX) preoperatively are theoretically at increased risk of complications after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The aim was to compare the occurrence of early postoperative complications among patients treated and not treated with IFX.
Methods: A retrospective analysis of different types of early postoperative complications in UC patients treated and not treated with IFX. Results: Between January 2006 and December 2012, 138 UC patients underwent surgical therapy.
Of these patients, 108 had restorative proctocolectomy and IPAA. Forty-seven patients received IFX preoperatively (IFX group), while 61 did not receive any IFX (No-IFX group).
In total, early complications occurred in 40.4% of patients in the IFX group, and in 44.3% in the No-IFX group. Using logistic regression analysis, no statistically significant difference was found in the occurrence of any particular type of both surgical and non-surgical complications.
Conclusion: We did not observe an increased occurrence of early postoperative complications in UC patients after a three-stage restorative proctocolectomy with IPAA.